Hims & Hers has performed well this year, as the company continues to revolutionize healthcare. HIMS stock price has risen by nearly 200% in this past year. Meanwhile, other healthcare companies like CVS Health Walgreens Boots Alliance, CVS Health have plunged. Will the stock continue to rise in value by 2025?
HIMS shares fell following a major FDA ruling
The entry of Hims & Hers into the weight-loss industry has spurred the stock’s price. It offers high quality products at a low cost.
The stock may soon be put under pressure, explaining why it has fallen by over 25% since its peak this year.
The Food and Drug Administration warned in a recent statement that they were concerned by the number of weight-loss drugs on the market. It expressed concern about compounds, saying that they were unapproved.
FDA reported adverse reactions related to compounded tripeptide and semaglutide. It is therefore likely that the Hims & Hers company will suffer because its weight-loss segment is amongst their fastest-growing.
Strong growth is being experienced by the company
The stock of Hims & Hers rose this year, as the company’s business continued to do well due to its vast total market. ,its major markets such as weight loss, hair fall, anxiety and sexual health, have an enormous total market. A report from Oxford found that more than 25% of American men had erectile problems.
According to estimates, millions of Americans struggle with weight. The CDC estimates that about 9,4% of Americans have an obesity issue. Further, people now feel more confident about buying the drugs online. This was not true a few short years ago.
The Hims share price is a good example of these trends. In 2019, its annual revenue was only $82.6 million, making it an extremely small company. Recent years, the company’s revenue has increased dramatically, reaching over $872 millions in 2023, and more than $1.2 billion for the last twelve months.
Recent results show that Hims & Hers revenues grew by 77% year-over-year to more than $401.6 million. Analysts believe that the growth will continue, as revenue for this quarter is expected to increase by over 90%.
Hims & Hers is expected to reach $1.45 billion in revenue this year and $2.03 billion by 2026. It is one of the fastest growing companies in the health care industry.
Hims & Hers has seen a profitable increase. It is estimated that the EPS for this quarter will increase to 22 cents, from $0.05 last year. The company’s EPS for this year will be 8 cents, and then 93 cents the next year. The company’s market capitalization of over $5 billion will be justified by this growth.
Hims & Hers Stock Price Analysis
On the daily chart, you can see that HIMS shares peaked in November at 35 dollars. It was as we expected that it lost some of its gains following the FDA ruling.
In the stock’s recent decline, it has retested an important level of support at $25.75. This was its high swing from June 17th. The pattern of a break-and-retest is one that is considered to be a bullish continuation sign.
Stock has been supported by the Exponential 50-day Moving Average. There are therefore chances that the stock could bounce back and test the key resistance level at $35, which is the high for the current year. The bullish outlook will be invalidated if the stock drops below $22, the current support level.
The post Does the Hims & Hers share price rise in 2025 or fall? This post may change as new information unfolds
This site is for entertainment only. Click here to read more
